#MSParis2017 – Sanofi to Present Long-term Data on Lemtrada and Aubagio Use

#MSParis2017 – Sanofi to Present Long-term Data on Lemtrada and Aubagio Use

New data on how Lemtrada (alemtuzumab) and Aubagio (teriflunomide) perform in a real-world setting will be the focus of Sanofi Genzyme when the company showcases its research at the upcoming 7th Joint ECTRIMS-ACTRIMS Meeting in Paris this week.

Researchers will also share information about the safety of a new investigational therapy, GLD52 (GZ402668), currently in a Phase 1 safety study.

“Lemtrada and Aubagio play important roles in the treatment of relapsing MS, and we look forward to presenting new long-term and real-world data at ECTRIMS to help deepen the MS community’s understanding of these two therapies,” Tom Snow, global head of multiple sclerosis for Sanofi Genzyme, said in a press release.

“In addition, we are continuously working to advance MS treatment and care with research efforts focused on unmet needs for relapsing and progressive forms of the disease,” Snow added.

The TOPAZ study (NCT02255656) is one of the main data sources for the upcoming presentations. The study, which follows relapsing MS patients who participated in the CARE MS-I and CARE MS-II extension study (NCT00930553), is a rich source of information on long-term outcomes.

Researchers will share various aspects of disease outcomes and magnetic resonance imaging (MRI) data from patients followed up to seven years, with some presentations focusing solely on those who switched from treatment with interferon beta-1a.

Among the Lemtrada highlights are findings demonstrating that Lemtrada does not appear to trigger birth defects.

Another presentation compared Lemtrada to Genentech’s Ocrevus (ocrelizumab) using a model that evaluated both the cost and effectiveness of the two drugs. The analysis suggests that Lemtrada more effectively treated relapsing MS and was also linked to lower costs over a 20-year period.

Aubagio studies also focused on long-term patient data, including in people with progressive forms of relapsing MS. Data from the Phase 3 TEMSO (NCT00134563), TOWER (NCT00751881), and the TEMSO extension (NCT00803049) showed that Aubagio stabilized disability progression in these patients over nearly a decade.

Other presentations homed in on Aubagio’s ability to slow brain tissue loss and improve cognitive outcomes.

Finally, Sanofi Genzyme shared initial data on its investigational antibody GLD52. The treatment is an updated form of Lemtrada, which scientists believe gives rise to fewer and milder infusion-related reactions.

Data from the Phase 1 study (NCT02282826), so far indicated that this might indeed be the case, as no severe reactions occurred in the 44 progressive MS patients in the trial.

For a complete list of Sanofi Genzyme’s presentations at the meeting, visit this link.

 

One comment

  1. Maurice Fortin says:

    Lemtrada, the very same “medicine” that was used for Chemotherapy (cancer patients such as leukemia) they reduced the amount of the active drug and upped the price of it when it was put for use for MS.

    lets see, less of the medicine but even higher cost, yep, they are there to chase riches not help patients they are there to be a billion dollar per quarter corporation (I read something about this a few months back)

    the other thing about ALL MS “treatments” the majority of them involve medicines that “do this, because we think it does that” or “we do not understand how it works exactly, but we believe it might be doing this” type BS.

    nothing like making people that need help guinea pigs at a couple thousand to tens ot hundreds of thousands $ per year for the “privilege” of being a guinea pig and “hoping” it does not destroy your immune system, liver, kidneys etc.

    even the testing methods they seem to use or at the least required are so very minimal and they just seem to want to rush to treat you instead of being fully invested into making sure it might not be something else instead.

    “get the people on nasty medicines and hope they get better, if not, we will just make more money off of them by treating what went wrong”

    MS is extremely “unknown” at this point and time, so the few potential treatments flagged for use in Canada or USA are not only crazy expensive (so big pharma can continue to make billions per year on “research” when the product costs so very little per dose) the potential side effects are crazy as heck.

    if they make you sick or injure you when you are made this guinea pig, what will they say or do, likely not much but “oops, sorry”

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This